A Study of Standard Drugs for Mycobacterium Avium Complex

Status Recruiting

Clinical Trial Summary

To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.

Clinical Trial Description

This research is being done to better understand several important aspects of treatment of Mycobacterium avium complex (MAC) lung infections using an early bactericidal activity (EBA) study design. MAC is an environmental bacteria that can cause chronic lung infection. Early bactericidal activity is the amount of bacterial killing that occurs during the first few weeks of antibiotic treatment. By collecting information about the EBA of azithromycin for MAC, the investigators will quantify the efficacy of azithromycin against pulmonary MAC. ;

Study Design

Related Conditions & MeSH terms

Mycobacterium Avium Complex
Mycobacterium avium-intracellulare Infection
Mycobacterium Infections

Clinical Trial Details

NCT number	NCT04287049
Study type	Interventional
Source	Johns Hopkins University
Contact	Kaylee Martin
Phone	(410) 614-2724
Email	kmart147@jh.edu
Status	Recruiting
Phase	Phase 2
Start date	February 24, 2020
Completion date	May 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05192057` - Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease	Phase 4
Withdrawn	`NCT01719042` - Improving Tolerance of Treatment of Pulmonary MAC Infections	Phase 2
Completed	`NCT00600769` - Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)	Phase 4
Recruiting	`NCT03236987` - CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections	Phase 3
Recruiting	`NCT03672630` - Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease	Phase 2/Phase 3
Completed	`NCT04685720` - A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients	N/A
Terminated	`NCT04553406` - Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease	Phase 2
Completed	`NCT00598962` - Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease	Phase 4
Recruiting	`NCT05824988` - Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Recruiting	`NCT02968212` - Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)	Phase 2